Detecting and characterizing melanoma cells in the bloodstream
Official title: Immuno-electrochemical Detection and Characterization of Melanoma Circulating Cells
Funded at Wm S. Middleton Memorial Veterans Hosp · NIH-10975910 · Data updated 2026-11-12
This study is looking at ways to find tiny cancer cells in the blood of people with melanoma, which can help doctors understand how the disease is spreading and improve monitoring, so patients can get the right care sooner.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wm S. Middleton Memorial Veterans Hosp NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | October 1, 2023 |
| Project end | September 30, 2027 |
| Funding year | 2025 |
| NIH project number | 5I01CX002393-02 |
| Project ID | NIH-10975910 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with melanoma, particularly those in early stages or at risk of developing metastatic disease.
✕Less likely to help
Patients with non-melanoma skin cancers or those who are not currently diagnosed with melanoma may not benefit from this research.
What this research studies
This research focuses on improving the detection of circulating tumor cells (CTCs) in patients with melanoma, which can indicate the presence of metastatic disease. By analyzing blood samples, the study aims to identify reliable biomarkers that can help assess and monitor the risk of melanoma progression. The approach involves advanced immuno-electrochemical techniques to enhance the sensitivity of CTC detection, potentially leading to earlier interventions for patients. The goal is to provide a better understanding of how melanoma spreads and to improve patient outcomes through more effective monitoring.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection of melanoma metastasis, allowing for timely and potentially life-saving treatments.
How similar studies have gone: Previous research has shown promise in using circulating tumor cells as biomarkers for cancer monitoring, indicating that this approach has potential for success.
Where this research is happening
-
Wm S. Middleton Memorial Veterans Hosp
Madison, United States Active
Researchers
- Principal investigator: Setaluri, Vijayasaradhi — Wm S. Middleton Memorial Veterans Hosp
- Study coordinator: Setaluri, Vijayasaradhi
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.